Organisational changes in KaroBio AB (PUBL)

STOCKHOLM, SWEDEN, February 4, 2015 - CEO Per Bengtsson has informed the Board of Directors of Karo Bio that he wants to step down from his current position with immediate effect. Per Bengtsson has been working as CEO since 2011 and the Board recognizes his excellent performance and contribution to the Company.

The Board of Karo Bio has decided to appoint Anders Lönner as Executive Chairman of the Board. His prime goal will be to develop and complement Karo Bio´s business platform with projects and products closer to the market. “My ambition and priority is to develop Karo Bio into a successful pharma company over the coming years. Together with the excellent team we are prepared to take on the challenges during the years to come” Anders Lönner commented.

Maria Sjöberg presently in charge of Karo Bio’s R&D is appointed new CEO. “It is very exciting to take the role as CEO and to work together with Anders Lönner and the team” Maria Sjöberg says.

CFO Henrik Palm is appointed as Executive Vice President.

The Board of Karo Bio

Maria Sjöberg, born 1964, employed 2011
Education: PhD Karolinska Institutet (Cell- and Molecular Biology), Associate Professor Karolinska Institutet (Molecular Endocrinology)
Previous experience: Vice President, R&D/Production Director SentoClone AB, Senior positions in research & development at Astra Zeneca and Karo Bio AB. Postdoctoral fellow at ICRF, London and Research Group Leader at Karolinska Institutet.

About Karo Bio
Karo Bio is a research and development company focused on innovative drugs for important medical needs. The world-leading knowledge of nuclear receptors as target proteins for the development of pharmaceuticals and their related mechanisms of action, are utilized for developing novel, more effective and safer pharmaceuticals. Karo Bio is active in preclinical development focused on the areas of neuropsychiatry, inflammation, autoimmune diseases and cancer. Karo Bio is based in Huddinge, Sweden. The company has around 24 employees and is listed on NASDAQ OMX Stockholm.

Karo Bio publishes this information in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was published on February 4, 2015 at 08:00 am CET.


About Us

Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.


Documents & Links